Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model

BACKGROUND: The oral immunomodulatory agent laquinimod is currently evaluated for multiple sclerosis (MS) treatment. Phase II and III studies demonstrated a reduction of degenerative processes. In addition to anti-inflammatory effects, laquinimod might have neuroprotective properties, but its impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilmes, Anna T., Reinehr, Sabrina, Kühn, Sandra, Pedreiturria, Xiomara, Petrikowski, Laura, Faissner, Simon, Ayzenberg, Ilya, Stute, Gesa, Gold, Ralf, Dick, H. Burkhard, Kleiter, Ingo, Joachim, Stephanie C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002998/
https://www.ncbi.nlm.nih.gov/pubmed/29903027
http://dx.doi.org/10.1186/s12974-018-1208-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002998/
https://www.ncbi.nlm.nih.gov/pubmed/29903027
http://dx.doi.org/10.1186/s12974-018-1208-3

Ejemplares similares